Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.

Alexander Drilon,Vivek Subbiah,Oliver Gautschi,Pascale Tomasini,Filippo de Braud,Benjamin J Solomon,Daniel Shao-Weng Tan,Guzmán Alonso,Jürgen Wolf,Keunchil Park,Koichi Goto,Victoria Soldatenkova, Sylwia Szymczak,Scott S Barker,Tarun Puri,Aimee Bence Lin,Herbert Loong,Benjamin Besse

Journal of Clinical Oncology（2023）

引用 37|浏览5

暂无评分

摘要

In a large cohort with extended follow-up, selpercatinib continued to demonstrate durable and robust responses, including intracranial activity, in previously treated and treatment-naive patients with fusion-positive NSCLC.

查看译文

关键词

selpercatinib,lung cancer,small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要